Cytotoxic agents Synergistic cytotoxicity of buthionine sulfoximine ( BSO ) and intensive melphalan ( L-PAM ) for neuroblastoma cell lines established at relapse after myeloablative therapy

Patients with high-risk neuroblastoma (NB) initially respond to aggressive, alkylator-based therapy only to die from recurrent disease that is refractory to chemotherapy, including alkylating agents. We examined the ability of buthionine sulfoximine (BSO)-mediated glutathione (GSH) depletion to modulate melphalan (LPAM) resistance in five NB cell lines… (More)